CHM Teabag Decrease Stroke Risk Among Hong Kong Elderly
Stroke, Risk Reduction, Elderly
About this trial
This is an interventional prevention trial for Stroke focused on measuring Stroke, Risk Reduction, Chinese Herbal Medicine, Automatic Retinal Image Analysis, Teabag
Eligibility Criteria
Inclusion Criteria: Age between 54-84y. With phlegm dampness constitution and blood stasis constitution on the TCM constitution test table. Stable vital signs without previous history of stroke. Sufficient sensorimotor and language competency for completing assessments. Exclusion Criteria: Allergic history to Chinese herbal drugs or a known allergy to the ingredients of the teabag. Taking any anticoagulants, such as warfarin. With unconsciousness, aphasia, and cognitive dysfunction. With a past history of brain diseases (e.g., mental illness, consciousness disorder due to head trauma, previous brain surgery, or spastic disease). With severe heart, liver, or kidney disease or bleeding disorders. With other serious diseases. Cataracts or other eye diseases that affected retinal image taking. Distressed with a flashlight or have experience with photosensitive seizures. Pregnancy or lactation female. Any physical examination findings, or history of any illness, or concomitant medications that, in the opinion of the study investigator, might not be suitable to participate in the study.
Sites / Locations
- Hong Kong Baptist University Mr. & Mrs. Chan Hon Yin Chinese Medicine Specialty Clinic and Good Clinical Practice CentreRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Chinese Herbal Medicine (CHM) teabag, Cluster 1
CHM teabag, Cluster 2
CHM teabag, Cluster 3
CHM teabag, Cluster 4
Intervention Cluster 1 is the first intervention arm designed to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population. It will receive 16 weeks of the intervention.
Intervention Cluster 2 is the second intervention arm designed to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population. It will receive 12 weeks of the intervention.
Intervention Cluster 3 is the third intervention arm designed to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population. It will receive 8 weeks of the intervention.
Intervention Cluster 4 is the fourth intervention arm designed to examine the efficacy and safety of CHM teabag in decreasing stroke risk by machine-learning-based retinal image analysis in elderly population. It will receive 4 weeks of the intervention.